Johnson & Johnsons's stock price may fall after the healthcare giant publishes its earnings report on Tuesday, January 26.
The successful launch of the COVID-19 vaccine this company has been developing could drive the stock price higher. Though early results look good. There are other issues that discourage investors and limit J&J's progress. They include lawsuits on other products, flat revenue numbers, and low RSR.
Consensus forecasts have EPS at $1.83 . If EPS is short of this target. We expect JNJ's price to go down.
No comments:
Post a Comment